Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 40

1.

[Treatment of metastatic progression following the synchronous occurrence of cutaneous and ocular primary melanomas].

Imrédi E, Plótár V, Szavcsur P, Pánczél G, Melegh K, Schlachter K, Liszkay G.

Orv Hetil. 2018 Apr;159(16):642-647. doi: 10.1556/650.2018.31018. Hungarian.

PMID:
29658281
2.

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.

Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators.

Lancet. 2018 Mar 31;391(10127):1263-1273. doi: 10.1016/S0140-6736(18)30475-6. Epub 2018 Mar 23.

PMID:
29576505
3.

Efficacy of Vemurafenib Treatment in 43 Metastatic Melanoma Patients with BRAF Mutation. Single-Institute Retrospective Analysis, Early Real-Life Survival Data.

Czirbesz K, Gorka E, Balatoni T, Pánczél G, Melegh K, Kovács P, Gézsi A, Liszkay G.

Pathol Oncol Res. 2017 Sep 29. doi: 10.1007/s12253-017-0324-1. [Epub ahead of print]

PMID:
28963614
4.

Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes).

Easton JD, Aunes M, Albers GW, Amarenco P, Bokelund-Singh S, Denison H, Evans SR, Held P, Jahreskog M, Jonasson J, Minematsu K, Molina CA, Wang Y, Wong KSL, Johnston SC; SOCRATES Steering Committee and Investigators.

Circulation. 2017 Sep 5;136(10):907-916. doi: 10.1161/CIRCULATIONAHA.117.028566. Epub 2017 Jun 27.

PMID:
28655834
5.

The 11-year long-term follow-up study from the randomized BENEFIT CIS trial.

Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Hemmer B, Fox EJ, Barkhof F, Schippling S, Schulze A, Pleimes D, Pohl C, Sandbrink R, Suarez G, Wicklein EM; BENEFIT Study Group.

Neurology. 2016 Sep 6;87(10):978-87. doi: 10.1212/WNL.0000000000003078. Epub 2016 Aug 10.

6.

Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.

Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, Jonasson J, Minematsu K, Molina CA, Wang Y, Wong KS; SOCRATES Steering Committee and Investigators.

N Engl J Med. 2016 Jul 7;375(1):35-43. doi: 10.1056/NEJMoa1603060. Epub 2016 May 10.

7.

[Psychological aspects of immunotherapies in the treatment of malignant melanoma].

Kovács P, Pánczél G, Melegh K, Balatoni T, Pörneczy E, Lõrincz L, Czirbesz K, Gorka E, Liszkay G.

Magy Onkol. 2016 Mar 2;60(1):22-7. Epub 2015 Dec 12. Hungarian.

8.

CHRONIC CEREBROSPINAL VENOUS INSUFFICIENCY--DISEASE OR MISDIAGNOSIS?

Panczel G, Szikora I, Berentei Z, Gubucz I, Marosfői M, Kovacs K, Rózsa A, Rózsa C.

Ideggyogy Sz. 2015 May 30;68(5-6):179-82.

PMID:
26182608
9.

Social support decreases depressogenic effect of low-dose interferon alpha treatment in melanoma patients.

Kovács P, Pánczél G, Balatoni T, Liszkay G, Gonda X, Bagdy G, Juhasz G.

J Psychosom Res. 2015 Jun;78(6):579-84. doi: 10.1016/j.jpsychores.2015.03.005. Epub 2015 Mar 14.

PMID:
25801845
10.

Thromboxane prostaglandin receptor antagonist and carotid atherosclerosis progression in patients with cerebrovascular disease of ischemic origin: a randomized controlled trial.

Bots ML, Ford I, Lloyd SM, Laurent S, Touboul PJ, Hennerici MG; Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin With Terutroban in Patients With a History of Ischemic Stroke or Transient Ischemic Attack Vascular Ultrasound Study Investigators.

Stroke. 2014 Aug;45(8):2348-53. doi: 10.1161/STROKEAHA.114.004775. Epub 2014 Jun 24.

11.

Psychological changes in melanoma patients during ipilimumab treatment compared to low-dose interferon alpha therapy-a follow-up study of first experiences.

Kovács P, Pánczél G, Borbola K, Juhász G, Liszkay G.

Pathol Oncol Res. 2014 Oct;20(4):939-44. doi: 10.1007/s12253-014-9777-7. Epub 2014 Apr 27.

PMID:
24771289
12.

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial.

Giovannoni G, Gold R, Selmaj K, Havrdova E, Montalban X, Radue EW, Stefoski D, McNeill M, Amaravadi L, Sweetser M, Elkins J, O'Neill G; SELECTION Study Investigators.

Lancet Neurol. 2014 May;13(5):472-81. doi: 10.1016/S1474-4422(14)70039-0. Epub 2014 Mar 19.

PMID:
24656609
13.

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.

Gold R, Giovannoni G, Selmaj K, Havrdova E, Montalban X, Radue EW, Stefoski D, Robinson R, Riester K, Rana J, Elkins J, O'Neill G; SELECT study investigators.

Lancet. 2013 Jun 22;381(9884):2167-75. doi: 10.1016/S0140-6736(12)62190-4. Epub 2013 Apr 4.

PMID:
23562009
14.

Results of Membrane-Activated Chelator Stroke Intervention randomized trial of DP-b99 in acute ischemic stroke.

Lees KR, Bornstein N, Diener HC, Gorelick PB, Rosenberg G, Shuaib A; MACSI Investigators.

Stroke. 2013 Mar;44(3):580-4. doi: 10.1161/STROKEAHA.111.000013. Epub 2013 Feb 7. Erratum in: Stroke. 2013 Mar;44(3) :e23.

15.

Assessment of antigen-specific and cross-reactive antibody responses to an MF59-adjuvanted A/H5N1 prepandemic influenza vaccine in adult and elderly subjects.

Bihari I, Pánczél G, Kovacs J, Beygo J, Fragapane E.

Clin Vaccine Immunol. 2012 Dec;19(12):1943-8. doi: 10.1128/CVI.00373-12. Epub 2012 Oct 17.

16.

[The importance of fine needle aspiration cytology in the management of recurrent and metastatic melanoma].

Pánczél G, Liszkay G, Borbola K, Balatoni T, Hunyadi J.

Orv Hetil. 2012 Sep 9;153(36):1419-23. doi: 10.1556/OH.2012.29434. Hungarian.

PMID:
22951409
17.

Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function.

Meltzer EO, Kuna P, Nolte H, Nayak AS, Laforce C; P04073 Study Investigators.

Eur Respir J. 2012 Feb;39(2):279-89. doi: 10.1183/09031936.00020310. Epub 2011 Aug 4.

18.

Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial.

Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox KM, Hennerici MG, Mattle HP, Rothwell PM, de Cordoüe A, Fratacci MD; PERFORM Study Investigators.

Lancet. 2011 Jun 11;377(9782):2013-22. doi: 10.1016/S0140-6736(11)60600-4. Epub 2011 May 25. Erratum in: Lancet. 2011 Jul 30;378(9789):402.

PMID:
21616527
19.

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.

Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, Cohen JA; TRANSFORMS Study Group.

Lancet Neurol. 2011 Jun;10(6):520-9. doi: 10.1016/S1474-4422(11)70099-0. Epub 2011 May 13.

PMID:
21571593
20.

Tiotropium versus salmeterol for the prevention of exacerbations of COPD.

Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Mölken MP, Beeh KM, Rabe KF, Fabbri LM; POET-COPD Investigators.

N Engl J Med. 2011 Mar 24;364(12):1093-1103. doi: 10.1056/NEJMoa1008378.

Supplemental Content

Loading ...
Support Center